Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06241326 | RECRUITING | Hepatocellular Carcinoma

Immunotherapy for Hepatocellular Carcinoma
Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Brief Summary:

This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.

Condition or disease

Hepatocellular Carcinoma

Immunotherapy

Intervention/treatment

Immunotherapy-based Combination Therapies

Detailed Description:

Hepatocellular carcinoma exhibits a significantly elevated incidence and mortality rate in China. Despite the Chinese population representing a mere 18.4% of the global population, the annual incidence of new liver cancer cases reaches a staggering 466,000 (55.4% of the global total), with 422,000 deaths (53.9% of the global total). Immunotherapy, particularly the implementation of immunotherapy-based combination treatment regimens, holds substantial therapeutic value in the management of hepatocellular carcinoma (HCC), leading to notable breakthroughs and advancements in the comprehensive treatment of liver cancer. The aim of this study is to evaluate the safety and efficacy of immunotherapy-based combination treatment regimens in Chinese hepatocellular carcinoma (HCC) patients under real-world clinical conditions. By collecting and analyzing data on the etiology, clinical characteristics, treatment modalities, and treatment outcomes of HCC patients receiving immunotherapy-based combination treatments in the clinical healthcare setting, the study seeks to provide valuable information regarding treatment patterns and effectiveness for hepatocellular carcinoma patients.

Study Type : OBSERVATIONAL
Estimated Enrollment : 11000 participants
Official Title : A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
Actual Study Start Date : 2024-03-01
Estimated Primary Completion Date : 2026-12-31
Estimated Study Completion Date : 2026-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Criteria
Inclusion Criteria
  • 1. Aged after 18 years (18 is included).
  • 2. Hepatocellular carcinoma diagnosed by pathology or imaging.
  • 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
  • 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
  • 5. Patients voluntarily enroll in this study.
Exclusion Criteria
  • 1. Pregnant or lactating women.
  • 2. Other conditions regimented at investigators' discretion.
Immunotherapy for Hepatocellular Carcinoma

Location Details

NCT06241326

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China, Jiangsu

Jiangsu Province Hospital

Nanjing, Jiangsu, China, 210029